MDxHealth SA (MDXH)
NASDAQ: MDXH · IEX Real-Time Price · USD
2.450
+0.100 (4.26%)
Apr 23, 2024, 4:30 PM EDT - Market closed
Company Description
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally.
Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications.
The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010.
MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
MDxHealth SA
| Country | Belgium |
| Founded | 2003 |
| IPO Date | Nov 4, 2021 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 252 |
| CEO | Michael K. McGarrity |
Contact Details
Address: Cap Business Center, Rue D'abhooz, 31, B-4040 Herstal, C9 00000 Belgium | |
| Phone | 949-271-9221 |
| Website | mdxhealth.com |
Stock Details
| Ticker Symbol | MDXH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $13.46 |
| CIK Code | 0001872529 |
| CUSIP Number | 58286E102 |
| ISIN Number | US58286E1029 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Michael K. McGarrity | Chief Executive Officer and Executive Director |
| Ron Kalfus | Chief Financial Officer |
| Joseph Sollee | Executive Vice President of Corporate Development and General Counsel |
| John A. Bellano | Chief Commercial Officer |
| Miriam Reyes | Executive Vice President of Operations |
| Dr. Jason Poole Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 12, 2024 | 6-K | Report of foreign issuer |
| Mar 6, 2024 | 6-K | Report of foreign issuer |
| Feb 16, 2024 | 6-K | Report of foreign issuer |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 8, 2024 | 6-K | Report of foreign issuer |
| Dec 19, 2023 | 6-K | Report of foreign issuer |
| Nov 27, 2023 | 6-K | Report of foreign issuer |
| Nov 24, 2023 | 8-A12B/A | Filing |
| Nov 24, 2023 | 25-NSE | Filing |
| Nov 15, 2023 | 6-K | Report of foreign issuer |